Sera Prognostics, Inc.

Sera Prognostics, Inc.

SERA·NASDAQ

$2.25

+9.5%
HealthcareMedical - Diagnostics & Research

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

At a Glance

Live Snapshot
Market Cap$85.74M
EPS-0.6700
P/E Ratio-3.35
Earnings Date08/05/2026

sera

Change in Working Capital

Last Annual Value

-546.00K

3-Year CAGR

-5%

5-Year CAGR

-12%

10-Year CAGR

17%

Sera Prognostics, Inc.

Sera Prognostics, Inc. Competitors Analysis of Change in Working Capital

SERA · NASDAQ
CompanyChange in Working Capital
CAGR 3Y
CAGR 5Y
CAGR 10Y
-546.00K
N/AN/AN/A 
6.06M
121.9%N/AN/A
-1.59M
N/AN/AN/A
6.28M
52.4%N/AN/A
DCGO logo
DocGo Inc.
NASDAQ:DCGO
81.66M
N/AN/AN/A
-4.10M
N/AN/AN/A
2.73M
N/A78.9%1.6%
4.76M
32.9%9.1%N/A
-1.41M
N/AN/AN/A
-2.81M
N/AN/AN/A
-3.15M
N/AN/AN/A
Sera Prognostics, Inc.

Sera Prognostics, Inc. Fair Value Envelope

SERA · NASDAQ

Our analysis suggests that SERA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.245, this represents a potential HIDDEN relative to our calculated worth for Sera Prognostics, Inc..

Intrinsic Value
Current Price: $2.245